OncoMatch/Clinical Trials/NCT06704555
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Is NCT06704555 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for follicular lymphoma.
Treatment: Tiselizumab · Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone — This was a single center, single arm, phase II study. Patients with previously untreated follicular lymphoma were enrolled from the department of lymphoma, Tianjin Medical University Cancer Institute and Hospital. The bulky disease was received radiation (dose:18～24Gy) before RCHOP. Patients began chemoimmunotherapy 1～2 weeks later than radiation. Treatment included Tiselizumab (200 mg iv d1) plus R-CHOP (rituximab 375 mg/m2 intravenous \[IV\] day 2, cyclophosphamide 750 mg/m2 IV day 3, doxorubicin 50 mg/m2 IV day 3, vincristine 1.4 mg/m2 \[maximum 2.0 mg total\] IV day 3, and prednisone 100 mg oral days 3-7, 21～28 days for one cycle ) for six cycles. Rituximab was given every 2 months to patients who were complete metabolic response /partial metabolic response（CMR/PMR）after first-line chemo until 2 years. Response was assessed by PET/CT scan after cycle 4 and cycle 6.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20 positive)
Histologically confirmed CD20 positive (+) follicular lymphoma
Disease stage
Required: Stage II, III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
WBC≥3.5×10^9/L, Platelets ≥ 75×10^9/L, ANC ≥ 1.0×10^9/L, Hgb ≥ 80 g/L
Kidney function
Calculated creatinine clearance ≥ 50 mL/min
Liver function
Bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5×ULN
Cardiac function
No class 3 (moderate) or class 4 (severe) cardiac disease as defined by NYHA; left ventricular ejection fraction ≥50%
Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration. 1. Hematological: WBC≥3.5×10^9/L, Platelets ≥ 75×10^9/L,Absolute Neutrophil Count (ANC) ≥ 1.0×10^9/L，Hemoglobin (Hgb) ≥ 80 g/L 2. Renal: Calculated creatinine clearance ≥ 50 mL/min 3. Hepatic: Bilirubin ≤ 1.5 × upper limit of normal (ULN), AST/ALT ≤ 2.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06704555 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages